BCL2 and B-cell non-Hodgkin lymphoma: Overexpression of the anti-apoptotic protein BCL-2 provides a survival advantage to malignant B cells and is involved in malignant B cell tumorigenesis, disease progression, and chemoresistance, making BCL-2 a potentially important therapeutic target for B -cell NHL.